...
首页> 外文期刊>Oncology letters >Three-way complex variant translocation involving short arm chromosome (1;9;22)(p36;q34;q11) in a chronic myeloid leukemia patient
【24h】

Three-way complex variant translocation involving short arm chromosome (1;9;22)(p36;q34;q11) in a chronic myeloid leukemia patient

机译:慢性髓性白血病患者涉及短臂染色体(1; 9; 22)(p36; q34; q11)的三向复杂变异易位

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic myeloid leukemia (CML) is a disease of the clonal hematopoietic stem cells caused by a balanced translocation between the long arms of chromosomes 9 and 22. Overall, 90-95% of CML patients present with a Philadelphia (Ph) chromosome t(9;22)(q34;q11) translocation and in addition, variant complex translocations, involving a third chromosome, are observed in 5-8% of CML patients. Cytogenic testing using bone marrow sample was performed and the FISH test was used for the detection of BCR-ABL fusion gene and complete blood analysis of CML patient was also performed. Results of hematological analysis showed the induced values of white blood cells (168,5000/mm(3)) and platelets (300,000/mm(3)) and FISH analysis test showed that 98% cells were positive for BCR/ABL gene translocation. The present study describes a three-way (1;9;22)(p36;q34;q11) Ph chromosome translocation in a 24-year-old female with CML. The patient, who was in the chronic phase of the disease, was treated with daily dose of 400 mg/dl with imatinib mesylateand was monitored constantly at various intervals over a 6-month period. Many studies reported that certain CML patents with variant translocation responded poorly to imatinib. In the current case report, the CML patient exhibited a suboptimal response to imatinib, denoting a poor prognosis.
机译:慢性粒细胞白血病(CML)是一种克隆的造血干细胞疾病,由9号和22号染色体的长臂之间的平衡易位引起。总体上,90-95%的CML患者出现了费城(Ph)染色体t(9) ; 22)(q34; q11)易位,此外,在5-8%的CML患者中观察到涉及第三条染色体的变体复杂易位。使用骨髓样品进行细胞原性检测,并使用FISH检测检测BCR-ABL融合基因,并对CML患者进行全血分析。血液学分析结果显示白细胞(168,5000 / mm(3))和血小板(300,000 / mm(3))的诱导值,FISH分析测试显示98%的细胞对BCR / ABL基因移位呈阳性。本研究描述了CML的24岁女性的三向(1; 9; 22)(p36; q34; q11)Ph染色体易位。处于该疾病慢性期的患者接受甲磺酸伊马替尼的每日剂量400 mg / dl的治疗,并在6个月的期间内以各种间隔不断进行监测。许多研究报告称,某些具有变异易位的CML专利对伊马替尼的反应较差。在当前的病例报告中,CML患者对伊马替尼的反应欠佳,预后不良。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号